Meta-analysis Suggests Hydroxychloroquine Benefit Outside Hospitals

By Reuters Staff

October 05, 2020

(Reuters) - When data from five randomized controlled trials of hydroxychloroquine for COVID-19 prevention or treatment were pooled for a meta-analysis, researchers found that early use of the drug by people who were not hospitalized yielded a statistically significant 24% reduction in risk of infection, hospitalization or death.

In the individual trials, hydroxychloroquine did not show a statistically significant impact on prevention or treatment.

"The meta-analysis pools together the studies and increases statistical power," said Dr. Joseph Ladapo of the David Geffen School of Medicine at UCLA, coauthor of a report posted on Wednesday on medRxiv ahead of peer review.

A weakness of the meta-analysis, Ladapo acknowledged, is that infections, hospitalizations and deaths were grouped together into a composite outcome. Combining all those events into one big number makes it more likely researchers will find that treatment had a significant effect.

Coauthor Dr. Harvey Risch of the Yale School of Public Health noted that seven nonrandomized controlled trials have also shown "statistically significant reduced risks with early outpatient use of hydroxychloroquine." Along with the meta-analysis, he told Reuters, "This is extremely strong evidence of benefit."

SOURCE: https://bit.ly/2SlHEeE medRxiv, online September 30, 2020.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....